Leo Pharma Reveals Groundbreaking Phase 3 Success for Hand Eczema
LEO Pharma, a leader in dermatology, has announced the publication of its DELTA 1 and DELTA 2 phase 3...
Jon Napitupulu
Truvian Health Is Making Healthcare More Affordable and Accessible
Access to healthcare remains a challenge, with limited availability of routine blood testing globally. Truvian Health aims to solve...
NIH, FDA Effort Unveils Revolutionary Parkinson’s Diagnosis Advancements
A new partnership aims to improve diagnosis and outcomes for Parkinson’s disease and related disorders. The Accelerating Medicines Partnership...
Crescita Therapeutics Partners with NanoPass to Enhance Medical Aesthetics Portfolio
Crescita Therapeutics and NanoPass have entered an exclusive distribution agreement to introduce MicronJetTM600, an advanced intradermal delivery device, to...
Cota and Texas Oncology Team Up for Enhanced AI Precision Medicine
COTA, Inc. and Texas Oncology’s Precision Health Informatics (PHI) have forged a collaboration to transform precision medicine within Texas...
Bayer’s Nubeqa Triumph: A Milestone in Prostate Cancer Treatment
The Phase III ARANOTE trial has demonstrated significant benefits for NUBEQA (darolutamide) in combination with androgen deprivation therapy (ADT)...
Scorpion Therapeutics Secure $150M for Cancer-Fighting Pipeline
Scorpion Therapeutics, a leading oncology company, announced a successful $150 million Series C financing round to advance its precision...
Predicta Biosciences Secures $5.2 Million Seed Funding for Non-Invasive Multiple Myeloma Diagnostics
Predicta Biosciences, a company focused on precision oncology, has secured an oversubscribed seed round of $5.2 million. The round...
Orum and Vertex Partner to Conquer Disease
Orum Therapeutics and Vertex Pharmaceuticals have agreed to develop novel targeted conditioning agents for gene editing using Orum’s Dual-Precision...
Phesi Data Emerging Clinical Trial Shift to Diabetes
Recent data from Phesi, a clinical development analytics company, reveals a significant shift in medical research priorities. Type 2...